- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Senesco Technologies, Inc. ("Senesco" or the "Company") SNT today reported financial results for the fiscal year ended June 30, 2008 ("Fiscal 2008").
Net loss for Fiscal 2008 was $4.6 million, or $0.26 per share, compared with a net loss of $3.3 million, or $0.19 per share, for the fiscal year ended June 30, 2007 ("Fiscal 2007"). This increase in net loss was primarily the result of an increase of $1.1 million in non-cash expenses associated with the outstanding convertible notes that were issued during Fiscal 2008 and an increase in operating expenses, which were slightly offset by an increase in revenues.
Fiscal 2008 and Recent Highlights
-- Senesco achieved all necessary milestones related to its private placements with YA Global Investments, LP and Stanford Venture Capital Holdings, Inc., and therefore received the $10 million gross proceeds under the terms of the securities purchase agreements.
-- Senesco announced positive results of preclinical animal studies focused on multiple myeloma. In the most recent studies undertaken, the Company used a combination therapy of its siRNA against Factor 5A as well as a plasmid of the Factor 5A gene encapsulated in a nanoparticle. Whether the combination therapy was injected intratumorally or systemically, human multiple myeloma tumors grown subcutaneously in the flanks of immunodeficient mice were reduced by approximately 95% versus tumors in untreated mice. Additionally, groups of treated mice were studied for up to three weeks after the last therapeutic injection and in mice whose tumors had regressed, the tumors did not regenerate.
-- The Company entered into its second and third license agreements with Bayer CropScience AG for the development and commercialization of cotton and rice, respectively, based on Senesco's proprietary gene technology.
-- Bayer CropScience successfully completed the first R&D milestone related to their use of Senesco's technology in Brassica oilseeds.
-- Senesco entered into a license agreement with Monsanto for the development and commercialization of corn and soy utilizing Senesco's proprietary gene technology.
Bruce Galton, President and Chief Executive Officer of the Company, said, "Our multiple myeloma pre-clinical program continues to move forward. We have seen some promising preclinical results this past fiscal year, and look forward to performing our planned multiple myeloma toxicology studies shortly. Subsequently, we will prepare and file our IND, which we anticipate will be within the next 12 months. Additionally, our technology is currently being used to potentially enhance the viability of major food and non-food crops. We believe we have a balanced business model and head into Fiscal 2009 with enthusiasm."
Revenue of $456,667 for Fiscal 2008 consisted of initial fees and milestone payments related to Senesco's agricultural development and license agreements. During Fiscal June 30, 2007, the Company reported revenue in the amount of $300,000. Such revenue consisted of initial fees, milestone payments and the amortized portion of previous milestone payments in connection with certain agricultural license agreements.
Research and development expenses during Fiscal 2008 were $1.8 million, compared with $1.2 million during Fiscal 2007, an increase of 46%. This increase resulted primarily from the expansion of Senesco's human health programs, including the Company's cancer research program, and an unfavorable exchange rate variance in connection with Senesco's research agreement with the University of Waterloo. The Company expects research and development expenses to continue to increase as it expands its research activities, particularly in the area of human health.
General and administrative expenses were $2.3 million during Fiscal 2008, compared with $2.4 million during Fiscal 2007, a decrease of 5%. This slight decrease was primarily due to a $161,000 decrease in stock-based compensation and a $69,000 decrease in depreciation and amortization. This was partially offset by increases in payroll and benefits, investor relations costs and professional fees.
At June 30, 2008, Senesco had cash, cash equivalents and investments of $6.2 million, and working capital of $5.7 million. Senesco expects to be able to operate according to the Company's current business plan for 13 months as of June 30, 2008.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
(tables to follow) SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED BALANCE SHEET June 30, 2008 2007 ASSETS Current Assets: Cash and cash equivalents $ 5,676,985 $ 408,061 Short-term investments 500,000 250,000 Prepaid expenses and other current assets 180,556 104,526 Total current assets 6,357,541 762,587 Property and Equipment, net 5,459 7,526 Intangibles, net 3,213,543 2,544,447 Deferred Financing Costs, net of amortization of $168,706 1,059,230 - Deferred Income Tax Asset, net of valuation allowance of $9,152,000 and $7,719,000, respectively - - Security Deposit 7,187 7,187 Total Assets $10,642,960 $3,321,747 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 370,167 $ 109,258 Accrued expenses 314,267 377,359 Deferred revenue - 16,667 Total current liabilities 684,434 503,284 Convertible Notes Payable, net of discount of $9,499,943 57 - Grant Payable 99,728 99,728 Other Liability 23,062 29,196 Total liabilities 807,281 632,208 Commitments Stockholders' Equity: Preferred stock - $0.01 par value; authorized 5,000,000 shares, no shares issued - - Common stock - $0.01 par value; authorized 100,000,000 and 60,000,000 shares, respectively, issued and outstanding 18,375,117 and 17,473,694, respectively 183,751 174,737 Capital in excess of par 39,874,958 28,136,342 Deficit accumulated during the development stage (30,223,030) (25,621,540) Stockholders' equity 9,835,679 2,689,539 Total Liabilities and Stockholders' Equity $10,642,960 $3,321,747 SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY (A DEVELOPMENT STAGE COMPANY) CONSOLIDATED STATEMENT OF OPERATIONS Year ended June 30, 2008 2007 2006 Revenue $ 456,667 $ 300,000 $ 66,666 Operating expenses: General and administrative 2,291,263 2,412,679 1,919,740 Research and development 1,764,426 1,208,321 1,566,267 Total operating expenses 4,055,689 3,621,000 3,486,007 Loss from operations (3,599,022) (3,321,000) (3,419,341) Noncash income - - - Sale of state income tax loss - net - - - Amortization of debt discount and financing costs (668,763) - - Interest expense - convertible Notes (434,154) - - Interest income - net 100,449 69,303 104,456 Net loss $(4,601,490) $(3,251,697) $(3,314,885) Basic and diluted net loss per common share $ (.26) $ (.19) $ (.21) Basic and diluted weighted- average number of common shares outstanding 17,660,466 16,916,918 15,469,881
For more information, please click here
Senesco Technologies, Inc.
Chief Financial Officer
Investor Relations Contact:
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016